Dernières nouvelles pour Becton Dickinson (NYSE:BDX) Stock

Becton Dickinson

Becton, Dickinson

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Becton, Dickinson and Company Common Stock

Becton Dickinson & Co

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is &#8220;undervalued,&#8221; but he is not going to <a href="https://www.benzinga.com/quote/MO/guidance">recommend tobacco stocks</a>.
On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. It beat the street view of $1.35. Quarterly sales of $5.334 billion (+1.3%) beat the analyst consensus estimate of $5.326 billion.
Cramer recommended selling Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
Super Micro Computer filed a FormNT 10-Q with the Securities and Exchange Commission, indicating that it's unable to file its 2025 fiscal-year first-quarter earnings on time.
When asked about The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), he said, &#8220;I prefer not to be in a stock that is going to lose a lot of money for a long time.&#8221;
According to Reuters, the company reportedly begins issuing layoff notices to employees affected by a major restructuring plan. The plan, which aims to reduce Boeing's global workforce by 17,000 jobs—approximately 10% of its total—comes as the heavily indebted aerospace <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41950702/boeing-reportedly-plans-furloughs-whats-going-on">giant seeks to cut costs</a>.
Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) has &#8220;broken down severely,&#8221; Cramer said. &#8220;If Robert F. Kennedy Jr. is going to be the head of HHS, then it's going to hurt a lot of vaccines, it could hurt a lot of their business.&#8221;
On Nov. 7, the company posted better-than-expected results for its fourth quarter.
&#8220;They have a lot of phase one stuff, and phase one is might early. Too early for me to bet on,&#8221; Cramer said when asked about IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>).
On Nov. 4, IDEAYA Biosciences reported a quarterly loss of 60 cents per share, compared to consensus estimates of a loss of 64 cents per share.
&#8220;I just don't know what is wrong,&#8221; Cramer said about AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>). &#8220;My god is this thing going lower.&#8221;
On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
Price Action:
<ul>
<li>Altria shares rose 0.3% to settle at $55.39 on Thursday.</li>
<li>Super Micro Computer shares dipped 11.4% to close at $18.01.</li>
<li>Boeing shares fell 1.3% to settle at $138.14 during the session.</li>
<li>Becton Dickinson shares fell 1.8% to close at $227.17 on Thursday.</li>
<li>IDEAYA Biosciences shares fell 3.4% to settle at $29.47 during the session.</li>
<li>AstraZeneca shares fell 0.4% to close at $65.04 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

IDYA

SMCI

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It

The U.S. stock market closed at record highs Thursday after the Federal Reserve's widely expected decision to lower interest rates and Fed Chair Jerome Powell's press conference where he reassured markets by dismissing concerns about his potential resignation or removal following the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">election of Donald Trump. </a>
The S&amp;P 500 — as tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — closed at 5,973 points, up 0.7% for the day.
Tech stocks outperformed the broader market, with the Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), surging 1.5% higher to an all-time high of 21,100 points.
Notably, the combined market capitalization of the Magnificent Seven — Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — soared to over $17 trillion, setting a new peak.
The Dow Jones stalled after Wednesday&#8217;s 3.6% rise, while small caps eased 0.4% following a 5.8% jump the previous day.
Top-performing sectors in the S&amp;P 500 were technology, up 1.8%, followed by communications services and consumer discretionary, both up by 1.3%. Financials, which rallied the most Wednesday, lagged on Thursday, down 1.5%.
<h3 class="wp-block-heading">Fed Cuts Rates, Powell Dismisses Concerns Over His Future </h3>
The Federal Reserve cut interest rates by 0.25% to 4.5%-4.75% as expected, a reduction in the pace of easing after the larger 0.5% cut in September.
The Fed recognized robust economic momentum, with the GDP rising by 2.8% in the second quarter, and resilient consumer confidence.
Powell downplayed weak October employment data, noting that near-zero job growth was largely due to temporary factors like strikes and hurricanes rather than underlying economic weakness.
Powell described the rate cut as part of a "further recalibration" of monetary policy, which he emphasized remains "restrictive." He hinted at the possibility of more easing in the future but refrained from signaling a specific rate cut at the December meeting, stressing a data-dependent approach.
When asked if he would resign if requested by Trump, Powell responded firmly, "No," reiterating that the president does not have the legal authority to remove the Fed chair.
Following Powell's comments, market-implied expectations for a 25-basis-point rate cut in December surged to 75%, recovering from Wednesday's post-election dip.
Treasury yields pulled back sharply, with the 10-year yield dropping 10 basis points to 4.33%, almost erasing the spike from the previous day.
The U.S. dollar weakened 0.7%, while gold prices, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), rebounded 1.8% after Wednesday&#8217;s 3% slump. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded up by 1% at 4:30 p.m. in New York, hitting a record-high of $76,990 during the session. 
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Thursday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg %</td>
</tr>
<tr>
<td>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)</td>
<td>233.00</td>
<td>14.95%</td>
</tr>
<tr>
<td>Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</td>
<td>13.20</td>
<td>13.69%</td>
</tr>
<tr>
<td>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>25.47</td>
<td>12.21%</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>9.38</td>
<td>11.91%</td>
</tr>
<tr>
<td>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)</td>
<td>607.76</td>
<td>10.64%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Losers On Thursday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>)</td>
<td>31.11</td>
<td>-17.86%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.93</td>
<td>-11.34%</td>
</tr>
<tr>
<td>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>57.09</td>
<td>-7.33%</td>
</tr>
<tr>
<td>Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>)</td>
<td>277.22</td>
<td>-5.71%</td>
</tr>
<tr>
<td>Becton, Dickinson and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>227.16</td>
<td>-5.38%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41824236/feds-interest-rate-cut-pace-expected-to-slow-economists-weigh-trumps-white-house-re">Fed&#8217;s Interest Rate Cut Pace Expected To Slow: Economists Weigh Trump&#8217;s White House Return</a></li>
</ul>
Wall Street bull illustration created using artificial intelligence via MidJourney.

Large Cap

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

Federal Reserve

Movers

ETFs

$BTC

AAPL

AMZN

EPAM

GOOG

GOOGL

MSFT

MTCH

NVDA

TSLA

VTRS

Wall Street Hits Record Highs After Powell's Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading

WIIM

BD shares are trading lower following Q4 earnings.

On Thursday, Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) reported fourth-quarter sales of&nbsp;$5.44 billion, up 6.9% year over year (+7.4% currency-neutral and 6.2% organic), beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $5.38 billion</a>.
&#8220;In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences&#8217; Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals,&#8221; said&nbsp;Tom Polen, chairman, CEO and president of BD.
&#8220;Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care.&#8221;
BD Medical segment&nbsp;sales increased to $2.84 billion, up 11.1%. Medication Management Solutions led organic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41801443/bd-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results" rel="noreferrer noopener">revenue growth of 8.6%</a>.
BD&nbsp;Life Sciences sales were almost flat to $1.34 billion, up 0.7% (+1.4% organic), and BD Interventional sales were up 4.7%&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38576402/bd-reports-second-quarter-fiscal-2024-financial-results" rel="noreferrer noopener">(+6.6%) to $1.26 billion</a>.
The MedTech player reported adjusted EPS of $3.81, up 11.4%, beating the consensus of $3.77.
Dividend: BD declared a quarterly dividend of $1.04 per share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31 to holders of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41801130/bd-board-increases-dividend-for-53rd-consecutive-year" rel="noreferrer noopener">record on December 9</a>.
Guidance: BD sees fiscal year 2025 sales of $21.9 billion-$22.1 billion compared to a consensus of $21.75 billion.
The company forecasts an adjusted EPS of $14.25-$14.60 versus the consensus of $14.34.
The company expects revenue growth of 8.9%-9.4% and currency-neutral adjusted revenue growth of 8.8%-9.3%, including the newly acquired <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39141141/bd-bolsters-portfolio-with-4-2b-cash-deal-for-edwards-lifesciences-critical-care-group-details" rel="noreferrer noopener">Advanced Patient Monitoring business</a>.
The company&#8217;s organic revenue growth guidance of 4.0%-4.5% includes absorbing an impact of about 125 basis points from an expected decline in revenues in&nbsp;China&nbsp;and Bioscience and Pharma market dynamics.
Price Action: BDX stock is down 3.96% at $230.55&nbsp;at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41816755/security-company-geos-q3-miss-lower-isap-participants-offset-by-strategic-contracts" target="_blank" rel="noreferrer noopener">Security Company GEO&#8217;s Q3 Miss: Lower ISAP Participants Offset By Strategic Contracts</a></li>
</ul>

Earnings

Guidance

Dividends

Health Care

General

Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth

Becton, Dickinson and Company shares are trading lower. The company reported Q4 financial results.

BD Sees FY25 GAAP Revenues $21.9B-$22.1B vs $21.75B Est., Adj EPS $14.25-$14.60 vs $14.34 Est.

Becton, Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) reported quarterly earnings of $3.81 per share which beat the analyst consensus estimate of $3.77 by 1.06 percent. The company reported quarterly sales of $5.437 billion which beat the analyst consensus estimate of $5.380 billion by 1.06 percent. This is a 6.88 percent increase over sales of $5.087 billion the same period last year.

Earnings Beats

Becton, Dickinson Q4 2024 Adj. EPS $3.81 Beats $3.77 Estimate, Sales $5.437B Beat $5.380B Estimate

The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024.&nbsp;

BD Boosts Quarterly Dividend By 9.5% From $0.95 To $1.04 Per Common Share

BD Launched The New BD Intraosseous Vascular Access System, Enabling Access For Rapid Delivery Of Fluids Or Medication In Critical Emergency Situations

Looking into the current session, Becton Dickinson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) shares are trading at $240.91, after a 0.50% spike. Moreover, over the past month, the stock went up by 1.87%, but in the past year, fell by 5.73%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729693827_0.png" alt="Past Year Chart" />

<h3>Evaluating Becton Dickinson P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Becton Dickinson has a lower P/E than the aggregate P/E of 261.98 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729693827_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Becton Dickinson

Shares of surgical tool and medical instrument stocks are trading higher in sympathy with Intuitive Surgical, which gained on strong Q3 earnings.

The automated solution from the BD and Hamilton collaboration standardizes traditionally manual processes and speeds the generation of material for genetic sequencing.
The solution includes the newly released BD&reg;&nbsp;OMICS-One XT WTA Assay and the Hamilton&nbsp;Microlab&nbsp;NGS STAR automated liquid handling platform. Because the NGS STAR is already installed in many laboratories and facilities worldwide, more researchers, processing samples across an array of genomics applications, can easily integrate the new automation-ready BD&reg;&nbsp;assay into existing workflows.

BD Reveals Commercial Launch Of New Robotics Solution That Will Enable Automation

Terms of the settlement agreement include cases in both the&nbsp;Rhode Island&nbsp;consolidated litigation and the federal multidistrict litigation in&nbsp;Ohio.&nbsp;
The aggregate amount payable pursuant to this settlement is within the company&#39;s current product litigation reserve for this matter and will be paid out over a multi-year period.
As a result, the settlement amount is already recorded as a liability within BD&#39;s consolidated balance sheet and the agreement will not result in an incremental charge to the company&#39;s consolidated income statement. BD believes this agreement is in the best interest of all parties and is structured to eliminate uncertainty for all stakeholders related to the settled cases. &nbsp;The hernia mass tort litigation represents a large majority of BD&#39;s total product litigation reserve.

Legal

BD Reaches Agreement To Resolve Vast Majority Of Its Existing Hernia Litigation, Terms Confidential; Expects Settlement Not To Change Cash Flow Goals Or Capital Allocation Strategy

Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Outperform and raises the price target from $286 to $290.

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on Becton Dickinson, Raises Price Target to $290

4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Becton Dickinson, presenting an average target of $270.0, a high estimate of $280.00, and a low estimate of $255.00. Surpassing the previous average price target of $265.00, the current average has increased by 1.89%.
<img src="https://www.benzinga.com/files/images/story/2024/1727794902_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Becton Dickinson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$255.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Becton Dickinson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Becton Dickinson's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>Get to Know Becton Dickinson Better</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Becton Dickinson: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Becton Dickinson's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Becton Dickinson's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.89%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Becton Dickinson's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Becton Dickinson's debt-to-equity ratio stands notably higher than the industry average, reaching 0.75. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Becton Dickinson Through 4 Analysts

Citigroup analyst Joanna Wiensch upgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Neutral to Buy and raises the price target from $255 to $275.

Upgrades

Citigroup Upgrades Becton Dickinson to Buy, Raises Price Target to $275

<ul>
<li>After implementing BD HealthSight Diversion Management software, the Ochsner facility observed a 55% increase in the number of charting discrepancies. This increase is attributed to the software's ability to track a broader range of discrepancies than was previously possible with existing procedures at the study site, such as whole dose waste, cancelled transactions and drugs dispensed after patient discharge.</li>
<li>The study also highlighted efficiency improvements in the facility's efforts to reconcile incidents of potential drug diversion in the operating room. Despite the increase in the volume of charting discrepancies, the percentage of incidents that were able to be resolved by the operating room analyst increased by 14% after software implementation and the number of cases requiring additional documentation by providers decreased by 10%. When a full investigation was required, the software reduced the time required for an auditor to review referred cases of potential diversion from an average of three business days to 50 minutes.</li>
<li>The study measured the facility's ability to identify, reconcile and investigate potential incidents of drug diversion across their 34 operating rooms where more than 55,000 surgeries are performed and more than 100,000 doses of controlled substances are dispensed annually.</li>
</ul>

Becton, Dickinson Announced New Data That Highlights How Its Advanced Artificial Intelligence Technology Can Help Health Systems Better Identify Incidents Of Controlled Substance Diversion In The Operating Room

Biotech

QGEN

QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples

Becton, Dickinson And Company Disclosed The Commercial Release Of The BD Neopak Xtraflow Glass Prefillable Syringe And The Latest Capacity Expansion Of The BD Neopak Glass Prefillable Syringe Platform

Becton Dickinson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) short percent of float has fallen 9.33% since its last report. The company recently reported that it has 1.98 million shares sold short, which is 0.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Becton Dickinson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724429720_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Becton Dickinson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Becton Dickinson's peer group average for short interest as a percentage of float is 4.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(BDX) - Analyzing Becton Dickinson's Short Interest

Josh Jennings, an analyst from TD Cowen, maintained the Hold rating on Becton Dickinson (BDX – Research Report). The associated price target is $26...

Becton Dickinson: Balancing Strong Core Performance with Uncertainties in Life Sciences and Future Guidance

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price ...

Becton Dickinson (BDX) Receives a Buy from Wells Fargo

Bank of America Securities analyst Travis Steed has reiterated their bullish stance on BDX stock, giving a Buy rating yesterday. Travis Steed's rat...

Cautious Optimism for Becton Dickinson: Buy Rating Maintained Amid Potential Growth Opportunities

Morgan Stanley analyst Patrick Wood has reiterated their bullish stance on BDX stock, giving a Buy rating yesterday. Patrick Wood's rating is based...

Becton Dickinson: Strong Performance and Promising Outlook Justify Buy Rating

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $280.00. The ...

Becton Dickinson (BDX) Gets a Buy from Stifel Nicolaus

Dividend Champion, Contender, And Challenger Highlights: Week Of November 10

Assessing MedTech impact from potential China tariffs

Becton, Dickinson and Company Q4: Shifting To High-Growth Areas

Least shorted S&P 500 stocks in October

Moderna continues to be the most shorted among S&P 500 healthcare stocks in October

AGCO

ALSN

AMGN

ARTNA

BOKF

BORT

CARR

CASY

CCOI

CGNX

CNOB

COST

CTAS

CTRA

DGICA

DGICB

EBMT

EFSI

EQIX

EVRG

EWBC

FANG

FCFS

FDBC

FMBH

GCBC

GEHC

GWRS

HESM

HOMB

HSIC

HTBI

HWKN

IBCP

IOSP

KLAC

LANC

LARK

MAIN

MASI

MPLX

MRNA

MSBI

MSCI

MSEX

MTRN

NVST

NXST

ORRF

OTIS

OTTR

PEBO

POOL

RPRX

RUSHA

SBAC

SBUX

SIGI

SMBC

SOLV

SPFI

SRCE

TAIT

TNDM

TSBK

UTMD

VALU

VCTR

VRTS

WABC

WING

WTRG

ZION

Press Releases

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion

BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation

BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results

BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research

BD Named Among the 100 Best Corporate Citizens of 2024

Women in Canada Can Now Collect Their Own Sample at Home for Cervical Cancer Screening

BD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Comments

Becton Dickinson

Actualités

Dernières nouvelles pour Becton Dickinson (NYSE:BDX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL